Agata Ribeiro-Lopes

6627, Antônio Carlos Ave
Belo Horizonte, MG 31270901, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Detection of SARS-CoV-2 epitope-specific CD8+ T cell responses in convalescent COVID individuals using HLA-A*02 dimers.

Detection of SARS-CoV-2 epitope-specific CD8+ T cell responses in convalescent COVID individuals using HLA-A*02 dimers.

Journal: Journal of immunological methods

Published: March 03, 2026

SARS-CoV-2 drives upregulation of EpCAM in respiratory epithelial cells with hypercellular profile during severe COVID-19.

SARS-CoV-2 drives upregulation of EpCAM in respiratory epithelial cells with hypercellular profile during severe COVID-19.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: December 20, 2025

Immune landscape of COVID-19 recovery: Nucleocapsid as a major target of CD8+ T cell antiviral responses in convalescent HLA-A*02+ individuals from Brazil.

Immune landscape of COVID-19 recovery: Nucleocapsid as a major target of CD8+ T cell antiviral responses in convalescent HLA-A*02+ individuals from Brazil.

Journal: Journal of leukocyte biology

Published: December 16, 2025

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.

Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Cannabidiol promotes fine-tuning of natural killer and monocytic cells subsets as well as cytokine storm during chikungunya virus exposure in vitro: Insights for putative therapeutic interventions.

Cannabidiol promotes fine-tuning of natural killer and monocytic cells subsets as well as cytokine storm during chikungunya virus exposure in vitro: Insights for putative therapeutic interventions.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 29, 2025

Correction to: HCV immunodominant peptide mapping reveals unique HLA‑A* 02‑restricted signatures: insights for CD8+ T‑cell‑based vaccines and immunotherapies.

Correction to: HCV immunodominant peptide mapping reveals unique HLA‑A* 02‑restricted signatures: insights for CD8+ T‑cell‑based vaccines and immunotherapies.

Journal: Immunogenetics

Published: April 22, 2025

A pain from the nose to the head: neurological commitment during long COVID.

A pain from the nose to the head: neurological commitment during long COVID.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: April 07, 2025

HCV immunodominant peptide mapping reveals unique HLA-A*02-restricted signatures: insights for CD8+ T-cell-based vaccines and immunotherapies.

HCV immunodominant peptide mapping reveals unique HLA-A*02-restricted signatures: insights for CD8+ T-cell-based vaccines and immunotherapies.

Journal: Immunogenetics

Published: October 24, 2024

IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya fever.

IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya fever.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: August 02, 2024

MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis.

MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis.

Journal: Frontiers in immunology

Published: January 19, 2024

New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19.

New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19.

Journal: Virus research

Published: October 07, 2023

Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8+ T cells.

Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8+ T cells.

Journal: Frontiers in immunology

Published: May 26, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026